share_log

HC Wainwright & Co. Reiterates Buy on Marinus Pharma, Maintains $27 Price Target

Benzinga ·  Apr 16 22:59

HC Wainwright & Co. analyst Douglas Tsao reiterates Marinus Pharma (NASDAQ:MRNS) with a Buy and maintains $27 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment